title: Development of a vaccine against cytomegalovirus infection and disease.
abstract: Human cytomegalovirus causes disabling congenital disease in neonates and severe complications in immunocompromised individuals, making it a high priority for vaccine development. A prophylactic vaccine needs to outperform natural immunity and a therapeutic vaccine needs to elicit rapid protective antiviral responses. This review highlights the three major approaches undertaken by vaccine developers-virus-derived, protein subunit, and gene-based approaches. Each approach offers a unique promise for a successful vaccine by eliciting either a broad immune response or inducing neutralizing antibody responses order(s) of magnitudes greater than natural immunity. A vaccine-elicited immunity is anticipated to have the robustness and duration sufficient to overcome cytomegalovirus infection.
authors.affiliation: GSK Vaccines, Rockville, MD, USA.
authors.forename: Kate
authors.initials: K
authors.lastname: Luisi
authors.affiliation: GSK Vaccines, Rockville, MD, USA.
authors.forename: Mayuri
authors.initials: M
authors.lastname: Sharma
authors.affiliation: GSK Vaccines, Rockville, MD, USA. Electronic address: dong.x.yu@gsk.com.
authors.forename: Dong
authors.initials: D
authors.lastname: Yu
mesh_terms: D003586:Cytomegalovirus Infections / Q000517:prevention & control* / Q000628:therapy*; D022482:Cytomegalovirus Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D055808:Drug Discovery / Q000639:trends*; D006801:Humans
chemical_list: D022482:Cytomegalovirus Vaccines